All News
Low COVID-19 Vaccine Risks in Rheumatic Patients
Data from the European Alliance of Associations for Rheumatology Coronavirus Vaccine registry shows that patients with with inflammatory or noninflammatory rheumatic and musculoskeletal disease have similar adverse event rates as the general public.
Read Article
Medscape: Physician Burnout Report 2022
The annual Medscape Physician Burnout & Depression survey has been published for 2022 and Rheumatology burnout stats have improved, now ranking 10th (middle of the pack).
Read Article
Positive Results from the DOA (Duloxetine in OsteoArthritis) Study
A pragmatic, open-label trial of osteoarthritis (OA) patients demonstrated that adding duloxetine treatment seems to be beneficial for end-stage knee OA patients with neuropathic-like symptoms (at risk of central sensitization).
Read Article
RheumNow Podcast - RWCS 2022 Roundup (2.19.2022)
Drs. Jack Cush and Artie Kavanaugh review the highlights of the RWCS (Rheumatology Winter Clinical Symposium) from Maui.
Read Article
Did Your Specialty Choose You?
Why did I end up a rheumatologist? Circumstance, personality types, horoscopes or what? A current study in BMJ sheds light on why.
Read Article
BMI Most Impairs Treatment Response in Rheumatoid Arthritis
Using a large cohort of rheumatoid arthritis (RA) patients, Tumor-Necrosis Factor inhibitors (TNFi) were compared to non-TNFi biologic therapies and showed that poorer responses were seen in obese and underweight patients, with no clear superiority of non-TNFi therapy over TNFi therapy in an
Read Article
Two Year Guselkumab Benefits in Psoriatic Arthritis
Patients enrolled in one of the pivotal trials of guselkumab (Tremfya) as therapy for psoriatic arthritis (PsA) and followed for 100 weeks continued to show significantly reduced symptoms relative to pretreatment baseline, researchers said.
Read Article
CV Risk Management in Rheumatic Disease Patients
The European League against Rheumatism (EULAR) has developed recommendations for cardiovascular risk (CVR) management in rheumatic disease patients based on literature review and expert consensus.
Read Article
Rheumatoid Arthritis Nonadherence is Multifactorial
The consequences of medication non-adherence (NA) in rheumatoid arthritis (RA) care are numerous and damaging. A 6-month prospective cohort study of RA patients shows NA to vary according to drug type and be related to psychological, communicational, logistic, sociodemographic or clini
Read Article
Hand OA and Heroes in Rheumatology (2.11.2022)
Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com.
Read Article
Hand Pain Related to Obesity and Inflammatory Markers
Arthritis & Rheumatology has published the results of the Nor-Hand study, showing that pain hand osteoarthritis (OA) was related to a higher body mass index (BMI) and also to inflammatory adipokines, such as leptin.
Read Article
ACR Updates Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With COVID
A Task Force from the ACR has provided an updated (version 3) guidance for the diagnosis and management of Multisystem Inflammatory Syndrome in Children (MIS-C), a COVID related condition characterized by fever, inflammation, and multiorgan dysfunction.
Read Article
Why Would Hand OA Be Less Severe in Black People?
Osteoarthritis (OA) of the hand was less severe according to objective and pain-related markers in Black patients versus those of other racial/ethnic groups after adjustment for known risk factors, researchers found.
Read Article
Vitamin D and the Risk of Autoimmune Diseases
The results of the VITAL study (presented at ACR 2021) are now published by BMJ, showing that vitamin D and omega 3 fatty acids reduce the overall risk of autoimmune disease (AID) in a population based intervention trial.
Read Article
Methotrexate Side Effects
Data came from the UK Rheumatoid Arthritis Medication Study (RAMS), a prospective cohort of early RA patients starting methotrexate (MTX) shows that in the first year, adverse events (AE) were common, but not serious.
Read Article
An Ounce of Prevention (2.4.2022)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. He discusses the GI side effects of IL-17 inhibitors, downstream revenues from rheumatology care and dietary prevention of gout.
Read Article
ACR/EULAR 2022 Classification Criteria for Microscopic Polyangiitis
The 2022 ACR/EULAR classification criteria for microscopic polyangiitis (MPA) have been developed, validated and are now ready for use in clinical research.
Read Article
Risk vs. Benefit Lessons from the ORAL Surveillance Study
In an editorial in the current edition of the NEJM, Dr. Jasvinder Singh comments on the Oral Surveillance trial (Ytterberg et al.), a 4-year randomized, open-label, noninferiority, postauthorization, safety end-point trial, in high risk active rheumatoid arthritis patients over age 50 years.
Read Article
MMWR: Booster Vaccine Efficacy in Immunosuppressed Patients
For adults aged ≥18 years who received 2 doses of an mRNA COVID-19 vaccine, a third dose increased vaccine effectiveness (prevention of hospitalization) among adults without (82% to 97%) and with immunocompromising conditions (69% to 88%), with near similar efficacy.
Read Article
Physical Therapy is More Cost-Effective than Intraarticular Steroids in Knee OA
A randomized trial compared the incremental cost-effectiveness of physical therapy and intra-articular glucocorticoid (IA GC) injection as initial treatment for knee osteoarthritis showed that physical therapy gained more quality-adjusted life-years compared with those receiving glucocortico
Read Article
